• Skip to primary navigation
  • Skip to content
  • Skip to footer
Gynesonics

Gynesonics

Advancing technology. Improving women's lives.

  • Our Company
    • About Us
    • Careers
    • Compliance
  • Our People
    • Management
    • Board of Directors
    • Investors
  • Our Technology
    • The Sonata System
    • Indications and Safety
    • Instructions for Use
    • Request for Medical or Scientific Information
  • Our News
    • Press Releases
    • In the News
    • Publications
    • 2022 Events
  • Contact Us

Press Releases

Aug 20, 2020

Gynesonics Announces Publication of OPEN Clinical Trial Results, Demonstrating No Intrauterine Adhesion Formation Following Treatment with the Sonata System

Clinical Study Demonstrates No Adhesion Formation at Second-Look Hysteroscopy Performed Six Weeks After Transcervical Fibroid Ablation with the Sonata System Redwood City, Calif. – August 20, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced the publication of the OPEN clinical trial results, demonstrating […]

Aug 17, 2020

Medical Device Executive Nelson Whistance Joins Gynesonics as Vice President of U.S. Sales

Redwood City, CA – August 17, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Nelson Whistance has been named Vice President of U.S. Sales.  Mr. Whistance reports directly to the President and CEO, Christopher M. Owens. “Nelson is a […]

Jul 20, 2020

Gynesonics Announces Rapid Expansion In Positive Payer Coverage for Sonata

More Than 50 Million Covered Lives Added in First 6 Months of 2020 Redwood City, CA, July 20, 2020 — Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that health insurance coverage of more than 50 million lives were added for the Sonata treatment […]

Jun 30, 2020

Gynesonics Announces Publication of CHOICES: A Comparative Study of the Sonata Treatment Versus Myomectomy

Sonata Demonstrates Significant Advantages in Reducing Procedure Time, Length of Stay and Procedure Related Costs Compared to Myomectomy Redwood City, CA, June 30, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced the peer reviewed publication of CHOICES, a comparative, case-matched healthcare economic study. […]

Jun 22, 2020

Sonata System Assists Facilities Impacted by the COVID-19 Pandemic in Restarting Elective Gynecologic Procedures

Positive Aspects of Transcervical Fibroid Ablation, Strong Clinical Results, Provides Facilities with Confidence in Treating Fibroids and Minimizing Potential Viral Risks – Procedural Volumes Increasing Redwood City, CA – June 22, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that its Sonata® System […]

Jun 4, 2020

Gynesonics Announces Publications on Healthcare Economic Analyses Demonstrating Cost Savings

The Sonata System provides advantages in reducing the index procedure cost, length of stay (LOS), prescription medications, complications and radiology costs versus hysterectomy and myomectomy. Redwood City, CA – June 4, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids announced the publication of healthcare […]

May 28, 2020

Gynesonics Receives FDA Clearance to Market Next Generation Sonata System 2.1

EARLY LAUNCH IN EUROPE CONTRIBUTES TO SIGNIFICANT PROCEDURAL GROWTH Redwood City, CA – May 28, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its next generation Sonata® […]

Nov 11, 2019

Gynesonics Announces Full Launch of New Sonata 2 System at 48th AAGL Global Congress

2-year Outcomes Data from the SONATA IDE Pivotal Trial To Be Presented, Demonstrating Significant and Sustained Symptom Relief REDWOOD CITY, Calif. – November 11, 2019 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today the full launch of the Sonata® 2 System in the United […]

Nov 8, 2019

Gynesonics Names Kelly U. Petrucci Vice President of Healthcare Economics and Market Access

Joins Experienced Team to Accelerate Global Launch of the new Sonata 2 System Redwood City, CA – November 8, 2019 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Kelly U. Petrucci has been named Vice President of Healthcare Economics and […]

Mar 5, 2019

Gynesonics Announces Five-Year Patient Outcomes with the Sonata System Published in Journal of Gynecologic Surgery

VITALITY Study Demonstrates the Long-Term Durability of Patient Outcomes  In Treating Symptomatic Uterine Fibroids Redwood City, CA – March 5, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas) today announced the publication of the VITALITY study in the Journal […]

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next »

Footer

  • Privacy Policy
  • Terms of Use
  • Patents
  • Safety Information

© Copyright 2023 Gynesonics · All Rights Reserved · WS 05198 Rev. J

This website uses cookies to provide you with the best browsing experience.

Find out more or adjust your settings.

Gynesonics
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Show details
Name Provider Purpose Expiration
moove_gdpr_popup Gynesonics via Moove GDPR Plugin This is used to save your cookie settings for this website. 12 months
__cf_bm Cloudflare The __cf_bm cookie is a cookie necessary to support Cloudflare Bot Management. As part of their bot management service, this cookie helps manage incoming traffic that matches criteria associated with bots. Cookie is set on websites using Cloudfare and it is related to rate limiting policies. less than 12m
Analytics Cookies

This website uses analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Show details
Name Provider Purpose Expiration
_ga, _gat, _gid, _ga_* Google Analytics These cookies enable analytics features in our suite (e.g., distinguish users, remember traffic information, and determine the start and end of a session). They are set for analytics measures on our website. We can take a timestamp of your website visit, track the source (e.g. search engine) you used to access our website, and the number of times you visit our website. 1-12 months
_gcl_au, _gat_gtag_UA_* Google Tag Manager These cookies helps us to enable functional requests on our website, such as the communications between our website and resources such as style, fonts, and images. As a cookie related to our Tag Manager, it collects your interaction with our resources (e.g. clicks and views) to help us understand your behavior on our website as well as to improve our aggregated analysis from interactions and campaigns. 1-12 months